Insmed Incorporated (NASDAQ:INSM) Receives $81.40 Average PT from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have received an average rating of “Buy” from the sixteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $81.53.

INSM has been the topic of several research reports. UBS Group lifted their price objective on shares of Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. JPMorgan Chase & Co. boosted their price target on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Thursday, August 29th. Finally, Morgan Stanley lifted their target price on Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, July 12th.

Insiders Place Their Bets

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the sale, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,882 shares of company stock valued at $5,765,446. Insiders own 4.60% of the company’s stock.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its position in Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 135 shares in the last quarter. CWM LLC grew its position in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 155 shares during the period. First Horizon Advisors Inc. increased its holdings in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares in the last quarter. Beacon Financial Advisory LLC raised its position in shares of Insmed by 4.6% in the second quarter. Beacon Financial Advisory LLC now owns 13,825 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 605 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Insmed by 1.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 38,232 shares of the biopharmaceutical company’s stock worth $1,037,000 after acquiring an additional 610 shares during the period.

Insmed Trading Up 1.2 %

Shares of NASDAQ INSM opened at $72.27 on Friday. Insmed has a twelve month low of $21.92 and a twelve month high of $80.53. The firm has a market cap of $10.74 billion, a PE ratio of -13.82 and a beta of 1.11. The business has a fifty day simple moving average of $74.03 and a two-hundred day simple moving average of $55.22. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. During the same period in the prior year, the firm earned ($1.78) EPS. Insmed’s quarterly revenue was up 17.0% compared to the same quarter last year. Analysts expect that Insmed will post -5.42 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.